Shay Shemesh
Fondatore presso NUVECTIS PHARMA, INC.
Patrimonio netto: 10 M $ in data 30/04/2024
Posizioni attive di Shay Shemesh
Società | Posizione | Inizio | Fine |
---|---|---|---|
NUVECTIS PHARMA, INC. | Direttore operativo | 27/07/2020 | - |
Fondatore | 27/07/2020 | - | |
Corporate Officer/Principal | 27/07/2020 | - |
Storia della carriera di Shay Shemesh
Precedenti posizioni note di Shay Shemesh
Società | Posizione | Inizio | Fine |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2015 | 01/01/2020 |
Consigliere Generale | 01/01/2015 | 01/01/2020 | |
KERYX BIOPHARMACEUTICALS | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Shay Shemesh
Bar-Ilan University | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Israele | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Founder | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
NUVECTIS PHARMA, INC. | Health Technology |
Aziende private | 2 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Shay Shemesh
- Esperienza